Cefpodoxime

Summary

Cefpodoxime (CHEMBL1672) is an approved small-molecule antibacterial drug (ATC J01DD13); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DD13
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 427.5 Da · C15H17N5O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1672
Name	Cefpodoxime
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6335986
ChEBI	CHEBI:3504
ATC	J01DD13
Molecular formula	C15H17N5O6S2
Molecular weight	427.5
InChIKey	WYUSVOMTXWRGEK-HBWVYFAYSA-N

SMILES: COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O

IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A third-generation cephalosporin antibiotic with methoxymethyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamino substituents at positions 3 and 7, respectively, of the cephem skeleton. Given by mouth as its proxetil ester prodrug, it is used to treat acute otitis media, pharyngitis, and sinusitis.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefpodoxima, Cefpodoxime, Epoxim, Orelox, Orelox paed, cefpodoxime, CEFPODOXIME

Patent coverage: 4,472 distinct patent families (17,039 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 5-hydroxytryptamine receptor 2C, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2C	6.92	AC50	120	nM	CHEMBL_ACT_25131627

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT00143533	PHASE1	COMPLETED	Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
NCT00194532	Not specified	COMPLETED	Cefpodoxime vs Ciprofloxacin for Acute Cystitis
NCT03098485	Not specified	COMPLETED	Healthy Patients & Effect of Antibiotics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).